Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 5, 2009, Pages 579-588

  Tomkin, G H ^a  

^a Beacon Hospital   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALBIGLUTIDE; ALBUMIN; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTAMIC ACID; HEMOGLOBIN A1C; HYBRID PROTEIN; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN;

ADD ON THERAPY; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DIABETIC PATIENT; DISTRIBUTION VOLUME; DIZZINESS; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYDROLYSIS; HYPOGLYCEMIA; INFLUENZA; INJECTION SITE REACTION; LABORATORY TEST; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RASH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING;

ALBUMINS; ANIMALS; AREA UNDER CURVE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PATENTS AS TOPIC;

EID: 70349923522     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. 254055 Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B J BIOL CHEM 1993 268 26 19650-19655
2. 336944 Principia Pharmaceutical Corp is formed to develop therapeutic proteins with prolonged activity. Centeon LLC PRESS RELEASE 1999 August 17
3. 492831 Albugon fusion protein: A long-acting analog of GLP-1 that provides lasting antidiabetic effect in animals. Bloom M, Bock J, Duttaroy A, Grzegorzewski KJ, Moore P, Ou Y, Wojcik S, Zhou X, Bell AC DIABETES 2003 52 Suppl 6 Abs 479-P
4. 520153 History of Aventis Behring - Saving lives for over a century. Aventis Behring LLC COMPANY WORLD WIDE WEB SITE 2004 January 26
5. 529791 Gastrotech Pharma and Lilly form collaboration to combat digestive conditions. Gastrotech Pharma A/S PRESS RELEASE 2004 March 31
6. 566694 Human Genome Sciences announces agreement with GlaxoSmithKline for development and commercialization of novel drug to treat diabetes. Human Genome Sciences Inc PRESS RELEASE 2004 October 26
7. 571425 A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Baggio LL, Huang QL, Brown TJ, Drucker DJ DIABETES 2004 53 9 2492-2500 •• Describes preclinical data demonstrating that albiglutide mimics the action of GLP-1 in vivo and regulates energy intake and glucose homeostasis.
8. 578140 Cell Therapeutics, Inc. (CTI) licenses lisofylline and related patent portfolio to DiaKine Therapeutics, Inc. for development in diabetes. Cell Therapeutics Inc PRESS RELEASE 2005 January 04
9. 580623 Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM DIABETES 2005 54 1 146-151
10. 598898 Amylin and Lilly announce FDA approval of Byetta (exenatide) injection. Amylin Pharmaceuticals Inc, Eli Lilly & Co PRESS RELEASE 2005 April 29
11. 644321 Human Genome Sciences receives milestone payment from GlaxoSmithKline for filing of GSK716155 IND application to begin phase 1 trials in the treatment of diabetes. Human Genome Sciences Inc PRESS RELEASE 2006 January 10
12. 744075 Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD AM J HEALTH-SYSTEM PHARM 2005 62 2 173-181
13. 760659 The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ, Nauck MA LANCET 2006 368 9548 1696-1705
14. 761108 Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Flint A, Raben A, Astrup A, Holst JJ J CLIN INVEST 1998 101 3 515-520
15. 796642 The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial. Zinman B, Hoogwerf BJ, Garcia SD, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG ANN INTERN MED 2007 146 7 477-485
16. 818426 Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Kim D, MacConell L, Zhuang DL, Kothare PA, Trautmann M, Fineman M, Taylor K DIABETES CARE 2007 30 6 1487-1493
17. 818499 Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I, Madsbad S DIABETES CARE 2007 30 6 1608-1610
18. 822258 Drug datasheet: Januvia. DRUG DATASHEET WEBSITE 2007 August 15
19. 835987 NCT00530309: Clinical assessment of GSK-716155 for type 2 diabetes mellitus. GlaxoSmithKline CLINICALTRIALS.GOV 2007
20. 870216 Company website: DiaKine Therapeutics. DiaKine Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2008 January 24
21. 879559 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Klonoff DC, Buse JB, Nielsen LL, Guan XS, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG CURR MED RES OPIN 2008 24 1 275-286
22. 880516 Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H DIABETES CARE 2004 27 5 1047-1053
23. 898523 Novartis reports higher sales and earnings in first quarter of 2008 showing healthcare portfolio well on the way to new growth cycle. Novartis AG PRESS RELEASE 2008 April 21
24. 915035 Pharmacokinetics, safety, and tolerability of albiglutide (Syncria), a long-acting GLP-1 mimetic, in healthy volunteers. Stewart MW, Matthews J, De Boever EH, Dobbins RL, Holland CH, Hodge RJ, Gutierrez MJ, Walker SE, Bush MA ANN MEET AM DIABETES ASSOC 2008 68 Abs 522-P
25. 941528 Albiglutide, a long-acting GLP-1 mimetic: Pharmacodynamics, pharmacokinetics, safety and tolerability in subjects with type 2 diabetes. Stewart MW, Matthews J, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland CH, Bush MA DIABETOLOGIA 2008 51 Suppl 1 Abs 870
26. 953142 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang DL, Porter L LANCET 2008 372 9645 1240-1250
27. 953166 Essentialis: Product pipeline. Essentialis Inc COMPANY WORLD WIDE WEB SITE 2008 October 16
28. 953541 Novartis delivers sustained strong performance in first nine months of 2008 underpinned by accelerating growth in pharmaceuticals. Novartis AG PRESS RELEASE 2008 October 20
29. 961383 Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. DeFronzo RA, Okerson T, Viswanathan P, Guan XS, Holcombe JH, MacConell L CURR MED RES OPIN 2008 24 10 2943-2952
30. 977564 Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Bush MA J CLIN ENDOCRINOL METAB 2008 93 12 4810-4817 •• Describes two clinical trials assessing albiglutide in patients with T2DM. In patients receiving albiglutide, fasting plasma glucose and glucose-weighted mean AUC were improved, while the frequency of adverse events was comparable with that observed for patients treated with placebo.
31. 981892 GSK delivers EPS of 104.7p before major restructuring. Dividend increased 8% to 57p. GlaxoSmithKline plc PRESS RELEASE 2009 February 05
32. 982955 Roche Annual Report 2008: Business report. Roche Holding AG ANNUAL REPORT 2009 January 23
33. 984671 GSK initiates phase III programme for novel type 2 diabetes medication, Syncria (albiglutide). GlaxoSmithKline plc PRESS RELEASE 2009 February 17
34. 984679 Human Genome Sciences to receive $9 million milestone payment related to GlaxoSmithKline initiation of phase 3 clinical trial of Syncria in type 2 diabetes. Human Genome Sciences Inc PRESS RELEASE 2009 February 17
35. 994587 Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Marre M, Shaw J, Brandle M, Bebakar WMW, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S DIABETIC MED 2009 26 3 268-278
36. 996227 Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ et al CLIN PHARMACOL THER 2005 78 6 675-688
37. 1002365 NCT00838903: Efficacy and safety of albiglutide in treatment of type 2 diabetes. GlaxoSmithKline plc CLINICALTRIALS.GOV 2009
38. 1002368 NCT00849056: Safety and efficacy of albiglutide in type 2 diabetes. GlaxoSmithKline plc CLINICALTRIALS.GOV 2009
39. 1002372 NCT00838916: A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes. GlaxoSmithKline plc CLINICALTRIALS.GOV 2009
40. 1003462 Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Gutierrez M, Stewart MW DIABETES OBESITY METAB 2009 11 5 498-505 • Describes a phase I clinical trial assessing albiglutide in healthy volunteers. The half-life of albiglutide favored once-weekly dosing, and the drug was well tolerated.
41. 1004083 Elucidation of sites transducing anorectic GLP-1 signals through determination of the central and peripheral actions of Albugon, a novel recombinant albumin-GLP-1 fusion protein. Baggio L, Brown T, Huang Q, Drucker D DIABETES 2003 52 Suppl 1 Abs 1389-P
42. 1013504 Safety, pharmacokinetics and pharmacodynamics of albiglutide in Japanese subjects with type 2 diabetes: A phase I/II study. Seino Y, Nakajima H, Miyahara H, Kurita T, Bush MA, Yang F, Stewart MW ANN MEET AM DIABETES ASSOC 2009 69 Abs 581-P
43. 1013805 The gastrointestinal adverse event profile of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes. Stewart MW, Reusch JE, Bush MA, Yang F, Rosenstock J ANN MEET AM DIABETES ASSOC 2009 69 Abs 598-P
44. 1013830 Albiglutide, a long-acting GLP-1 receptor agonist, improves glycemia in type 2 diabetes: Time-course analysis. Reusch JEB, Rosenstock J, Bush MA, Yang F, Stewart MW ANN MEET AM DIABETES ASSOC 2009 69 Abs 461-P
45. 1016889 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Buse JB, Rosenstock JR, Sesti GS, Schmidt WE, Montanya EM, Brett JB, Zychma, Blonde LB LANCET 2009 374 9683 39-47
46. 1018664 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V, Manley SE, Neil A, McElroy K, Wright D, Kohner E et al LANCET 1998 352 9131 837-853
47. 1018826 GLP-1 receptor agonists for type 2 diabetes. De Block CE, Van Gaal LF LANCET 2009 374 9683 4-6
48. 1021536 Takeda receives FDA complete response letter for alogliptin, an investigational treatment for type 2 diabetes. Takeda Pharmaceutical Co Ltd PRESS RELEASE 2009 June 26
49. 1022638 Fact sheet No.312: Diabetes. World Health Organization INTERNET SITE 2008 November 30
50. 1022872 Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide (Syncria), a long-acting GLP-1 mimetic, in subjects with type 2 diabetes. Stewart MW, Matthews J, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland CH, Bush MA DIABETES 2008 57 Abs 519-P
51. 1022874 The potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly and monthly dosing. Rosenstock J, Reusch JEB, Bush MA, Yang F, Stewart MW DIABETES 2009 58 Abs 163-OR
52. 1023104 Diabetes - A global threat. [No authors listed] LANCET 2009 373 9677 1735
53. 1023127 Incretins and other peptides in the treatment of diabetes. Todd JF, Bloom SR DIABETIC MED 2007 24 3 223-232
54. 1023135 Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A AM J PHYSIOL - ENDOCRINOL METAB 2004 287 6 E1209-E1215
55. 1023162 Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: A double-blind placebo-controlled study. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R DIABETES CARE 2009 32 7 1237-1243
56. 1023166 The role of incretins in glucose homeostasis and diabetes treatment. Kim W, Egan JM PHARMACOL REV 2008 60 4 470-512
57. 1023167 Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Van Gaal LF, Gutkin SW, Nauck MA EUR J ENDOCRINOL 2008 158 6 773-784
58. 1023168 Albumin binding as a general strategy for improving the pharmacokinetics of proteins. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA J BIOL CHEM 2002 277 38 35035-35043
59. 1023891 New drug application for exenatide once weekly accepted for review by FDA. Amylin Pharmaceuticals Inc; Eli Lilly & Co; Alkermes Inc PRESS RELEASE 2009 July 07
60. 1026464 Lifetime risk and projected population prevalence of diabetes. Magliano DJ, Shaw JE, Shortreed SM, Nusselder WJ, Liew D, Barr ELM, Zimmet PZ, Peeters A DIABETOLOGIA 2008 51 12 2179-2186
61. 1026797 Taking a closer look at the pancreas. Coppieters K, von Herrath M DIABETOLOGIA 2009 51 12 2145-2147
62. 1026805 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK prospective diabetes study group. BMJ (CLINICAL RES ED) 1998 317 7160 703-713
63. 1026810 The metabolic syndrome - From insulin resistance to obesity and diabetes. Gallagher EJ, LeRoith D, Karnieli E ENDOCRINOL METAB CLIN N AM 2008 37 3 559-579
64. 1026811 Glycaemic control in type 2 diabetes - Not for sidelining. Narendran P DIABETIC MED 2008 25 6 639-642
65. 1026812 Addressing insulin resistance in type 1 diabetes. Pang TTL, Narendran P DIABETIC MED 2008 25 9 1015-1024
66. 1026815 Physical activity in the prevention of type 2 diabetes - The Finnish diabetes prevention study. Laaksonen DE, Lindstrom J, Lakka TA, Eriksson JG, Niskanen L, Wikstrom K, Aunola S, Keinanen- Kiukaanniemi S, Laakso M, Valle TT, Ilanne-Parikka P et al DIABETES 2005 54 1 158-165
67. 1026817 Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Bailey CJ DIABETES OBESITY METAB 2005 7 6 675-691
68. 1026818 Mechanisms of action of metformin in type 2 diabetes and associated complications: An overview. Correia S, Carvalho C, Santos MS, Seica R, Oliveira CR, Moreira PI MINI REV MED CHEM 2008 8 13 1343-1354
69. 1026911 Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic-islets. Schmidt WE, Siegel EG, Creutzfeldt W DIABETOLOGIA 1985 28 9 704-707
70. 1026917 Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Orskov C, Poulsen SS, Moller M, Holst JJ DIABETES 1996 45 6 832-835
71. 1026920 Clinical application of incretin-based therapy: Therapeutic potential, patient selection and clinical use. Kendall DM, Cuddihy RM, Bergenstal RM AM J MED 2009 122 6 Suppl 1 37-50
72. 1027059 Cytokine and cytokine-like inflammation markers, endothelial dysfunction and imbalanced coagulation in development of diabetes and its complications. Goldberg RB J CLIN ENDOCRINOL METAB 2009 94 9 3171-3182
73. 1027112 Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, Shannon RP J PHARMACOL EXP THER 2005 312 1 303-308
74. 1027125 Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP CIRCULATION 2004 110 8 955-961
75. 1027126 Isolation and characterization of exendin-4, an exendin-3 analog, from heloderma-suspectum venom - Further evidence for an exendin receptor on dispersed acini from guinea-pig pancreas. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP J BIOL CHEM 1993 267 11 7402-7405
76. 1027214 Thiazolidinediones and clinical outcomes in type 2 diabetes. Retnakaran R, Zinman B LANCET 2009 373 9681 2088-2090
77. 1028963 Good first six months in 2009 for Boehringer Ingelheim - Successful products Spiriva, Micardis and Flomax secure good growth. Boehringer Ingelheim Corp PRESS RELEASE 2009 July 28
78. 1032006 Novo Nordisk: Half-yearly report. Novo Nordisk A/S PRESS RELEASE 2009 August 06
79. 1032778 Translating ADA/EASD guidelines and the ACE/AACE road maps into primary care of patients with type 2 diabetes. Robertson C JNP 2008 4 9 661-671
80. 1032832 Albinterferon halfa-2b: A genetic fusion protein for the treatment of chronic hepatitis C. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG NAT BIOTECHNOL 2007 25 12 1411-1419
81. 1033089 The potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M DIABETES CARE 2009 doi:10.2337/dc09-0366
82. 1035415 Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL COCHRANE DATABASE SYST REV 2008 2 CD006739
83. 1036687 Drug development update: Albiglutide. GlaxoSmithKline plc COMPANY COMMUNICATION 2009 August 07